Evidence mapPaperPMID 41719400Full record

ArticleScience advances2026

Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and

Sabrina Y Camp, Meng Xiao He, Michael S Cuoco, Amanda E Garza, Sherin Xirenayi, Ziad Bakouny, Eddy Saad, Jad El Masri, Erica Pimenta, Kevin Meli and 19 more

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Sabrina Y CampDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9695-5527
Meng Xiao HeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Michael S CuocoBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.ORCID 0000-0003-2163-5120
Amanda E GarzaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0001-8557-8765
Sherin XirenayiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0009-0000-1970-6554
Ziad BakounyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0003-1906-5704
Eddy SaadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0001-8700-9312
Jad El MasriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Erica PimentaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9684-6486
Kevin MeliDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9579-3829
Chris LabakiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9584-8455
Breanna M TitchenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-1569-0513
Yun Jee KangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jack HorstDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0009-0001-5854-1825
Rachel TrowbridgeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Erin ShannonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Karla HelvieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Aaron R ThornerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9160-7881
Sébastien VigneauDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9091-2067
Angie MayorgaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jahnavi KodaliDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Hannah LachmayrDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0003-1850-9019
Meredith BemusDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Pengsheng ChenMOE Key Laboratory of Bioinformatics, Center for Synthetic and Systematic Biology, School of Life Sciences, Tsinghua University, Beijing, China.ORCID 0000-0003-1577-8854
Haiteng DengMOE Key Laboratory of Bioinformatics, Center for Synthetic and Systematic Biology, School of Life Sciences, Tsinghua University, Beijing, China.ORCID 0000-0001-9496-1280
Jihye ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9201-3217
Kevin BiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0009-0000-8260-2264
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-0201-4444

Funding

The Patient-Reported Outcomes, Community-Engagement and Language (PRO-CEL) CoreP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · 1985 to 2025
$88.4M
Physician Scientist Training in Cancer ResearchT32CA009172 · DANA-FARBER CANCER INSTITUTE · 1985 to 2025
$4.6M
Molecular origins and evolution to treatment resistance in genitourinary cancersR50CA265182 · DANA-FARBER CANCER INST · 2025 to 2025
$330k
NCI NIH HHS P30 CA008748NCI NIH HHS R50 CA265182NCI NIH HHS T32 CA009172
6 · The paper itself

Abstract

Transcriptional programs in renal cell carcinoma (RCC) have been linked to tumor heterogeneity and clinical outcomes, but analogous efforts to define chromatin programs shaping disease biology have been limited. Here, we generated single-cell ATAC-seq profiles from patients with RCC and integrated them with three previously published datasets to identify chromatin programs in tumor cells. We identified an interferon response program enriched in

Indexed as

Carcinoma, Renal CellEpigenesis, GeneticInterferonsKidney NeoplasmsTumor Suppressor ProteinsUbiquitin ThiolesteraseCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMutationPrognosisSignal TransductionSingle-Cell AnalysisTumor MicroenvironmentBAP1 protein, humanInterferonsTumor Suppressor ProteinsUbiquitin Thiolesterase

Identifiers

PMID41719400
PMCPMC12922754

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.